Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib in B-cell lymphoma patients intolerant to ibrutinib/acalabrutinib
NCT04116437Phase 2Completed
- Sponsor
- BeiGene
- Start
- Oct 2019
- Primary completion
- Jan 2026
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zanubrutinib in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Waldenström macroglobulinemia (WM) and 2 more, sponsored by BeiGene. Primary endpoint: Recurrence and change in severity of treatment-emergent Adverse Events of interest at 24 months. Started Oct 2019; status: completed.
02
Drugs
zanubrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)Waldenström macroglobulinemia (WM)mantle cell lymphoma (MCL)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT04116437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04116437.